Role of carnitine in cancer chemotherapy-induced multiple organ toxicity

Saudi Pharmaceutical Journal

Volumn 18, Issue 4, 2010, Pages 195-206

  Sayed Ahmed, Mohamed M ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCARNITINE; BLEOMYCIN; CARBOPLATIN; CARNITINE; CISPLATIN; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; FATTY ACID BINDING PROTEIN; HEART FATTY ACID BINDING PROTEIN; HEAT SHOCK PROTEIN 25; IFOSFAMIDE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PROPIONYLCARNITINE; UNCLASSIFIED DRUG;

BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER FATIGUE; CARDIOMYOPATHY; CARDIOTOXICITY; CARNITINE DEFICIENCY; CHEMICAL STRUCTURE; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG EXCRETION; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG UPTAKE; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; GENE EXPRESSION; HEPATORENAL SYNDROME; HUMAN; HYPERLIPIDEMIA; KIDNEY FIBROSIS; LONG TERM CARE; LUNG FIBROSIS; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NONHODGKIN LYMPHOMA; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR; SINGLE DRUG DOSE; THORAX RADIOGRAPHY;

EID: 84755161297     PISSN: 13190164     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsps.2010.07.008     Document Type: Review

References (125)

1. Abd-Allah A.R., Al-Majed A.A., Al-Yahya A.A., Fouda S.I., Al-Shabanah O.A. L-Carnitine halts apoptosis and myelosuppression induced by carboplatin in rat bone marrow cell cultures (BMC). Arch. Toxicol. 2005, 7:406-413.
2. Abdel-aleem S., El-Merzabani M.M., Sayed-Ahmed M., Taylor D.A., Lowe J.E. Acute and chronic effects of adriamycin on fatty acid oxidation in isolated cardiac myocytes. J. Mol. Cell. Cardiol. 1997, 29:789-797.
3. Ahmad S., Robertson H.T., Golper T.A., Wolfson M., Kurtin P., Katz L.A., Hirschberg R., Nicora R., Ashbrook D.W., Kopple J.D. Multicenter trial of L-carnitine in maintenance hemodialysis patients II. Clin. Biochem. Effects Kid. Intern. 2001, 38:912-918.
4. Alberts D.S., Yel-Mei P., Moon T.E., Bressler R. Carnitine prevention of adriamycin toxicity in mice. Biomedicine 1978, 29:256-258.
5. Aleisa A.M., Al-Majed A.A., Al-Yahya A.A., Al-Rejaie S.S., Bakheet S.A., Al-Shabanah O.A., Sayed-Ahmed M.M. Reversal of cisplatin-induced carnitine deficiency and energy starvation by propionyl-L-carnitine in rat kidney tissues. Clin. Exp. Pharmacol. Physiol. 2007, 34:1252-1259.
6. Al-Harbi M.M., Al-Gharably N.M., Al-Shabanah O.A., Al-Bekairi A.M., Osman A.M., Tawafik H.N. Prevention of doxorubicin-induced myocardial and haematological toxicities in rats by the iron chelator desferrioxamine. Cancer Chemother. Pharmacol. 1992, 31:200-204.
7. Al-Majed A.A., Sayed-Ahmed M.M., Al-Yahya A.A., Aleisa A.M., Al-Rejaie S.S., Al-Shabanah O.A. Propionyl-L-carnitine prevents the progression of cisplatin-induced cardiomyopathy in a carnitine-depleted rat model. Pharmacol. Res. 2006, 53:278-286.
8. Al-Majed A.A. Carnitine deficiency provokes cisplatin-induced hepatotoxicity in rats. Basic Clin. Pharmacol. Toxicol. 2007, 100:145-150.
9. Al-Shabanah O., Mansour M., El-Kashef H., Al-Bekairi A. Captopril ameliorates myocardial and hematological toxicities induced by adriamycin. Biochem. Mol. Biol. Int. 1998, 17:419-427.
10. Altun Z.S., Güneş D., Aktaş S., Erbayrktar Z., Olgun N. Protective effects of acetyl-L-carnitine on cisplatin cytotoxicity and oxidative stress in neuroblastoma. Neurochem. Res. 2010, 35(3):437-443.
11. Arafa H.M. Carnitine deficiency aggravates carboplatin nephropathy through deterioration of energy status, oxidant/anti-oxidant balance, and inflammatory endocoids. Toxicology 2008, 254:51-60.
12. Arcamone F., Franceschi G., Tenco S., Selva S. Adriamycin (14-hydroxy daunorubicin), a novel antitumour antibiotic. Tetrahedron Lett. 1969, 13:1007-1010.
13. Arsenian M.A., New P.S., Cafasso C.M. Safety, tolerability, and efficacy of a glucose-insulin-potassium-magnesium-carnitine solution in acute myocardial infarction. Am. J. Cardiol. 1996, 78:477-479.
14. Bach A.C., Schirardin H., Sihr M.O., Storck D. Free and total carnitine in human serum after oral ingestion of L-carnitine. Diabetes Metab. 1983, 9:121-124.
15. Beanlands R.S., Shaikh N.A., Wen W.H., Dawood F., Ugnat A.M., McLaughlin P.R., Carere R., Liu P.P. Alterations in fatty acid metabolism in adriamycin cardiomyopathy. J. Mol. Cell. Cardiol. 1994, 26:109-119.
16. Bernardini I., Rizzo W.B., Dalakas M., Bernar J., Gahl W.A. Plasma and muscle free carnitine deficiency due to renal Fanconi Syndrome. J. Clin. Invest. 1985, 75:1124-1130.
17. Bianchi G., Vitali G., Caraceni A., Ravaglia S., Capri G., Cundari S., Zanna C., Gianni L. Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine. Eur. J. Cancer 2005, 41:1746-1750.
18. Bizzi A., Ceriani L., Gerundino M., Spina A., Tacconi M.T., Veneroni E. Adriamycin causes hyperlipemia as a consequence of nephrotoxicity. Toxicol. Lett. 1983, 18:291-300.
19. Bohles H., Evangeliou A., Bervoets K., Eckert I., Sewell A. Carnitine esters in metabolic disease. Eur. J. Pediatr. 1994, 153:S57-S61.
20. Boonsanit D., Kanchanapangka S., Buranakarl C. L-carnitine ameliorates doxorubicin-induced nephritic syndrome in rats. Nephrology (Carlton) 2006, 11(4):313-320.
21. Brady L.J., Brady P.S. Hepatic and cardiac carnitine palmitoyltransferase activity. Effects of adriamycin and galactosamine. Biochem. Pharmacol. 1987, 36:3419-3423.
22. Brass E.P. Interaction of carnitine and propionate with pyruvate oxidation by hepatocytes from clofibrate-treated rats: importance of coenzyme A availability. J. Nutr. 1992, 122:234-240.
23. Brass E.P. Pivalate-generating prodrugs and carnitine homeostasis in man. Pharmacol. Rev. 2002, 54:589-598.
24. Bremer J. Carnitine metabolism and function. Physiol. Rev. 1983, 63:1420-1479.
25. Bremer J. Carnitine in intermediary metabolism. Reversible acetylation of carnitine by mitochondria. J. Biol. Chem. 1962, 237:2228-2231.
26. Bremer J. Carnitine in intermediary metabolism. The metabolism of fatty acid esters of carnitine by mitochondria. J. Biol. Chem. 1962, 237:3628-3632.
27. Bremer J. Carnitine in intermediary metabolism-the biosynthesis of palmitoyl-carnitine by cell sub-fractions. J. Biol. Chem. 1963, 238:2774-2779.
28. Brock N., Stekar P.J., Scheef W. Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention. III. Profile of action of sodium 2-mercaptoethane sulfonate (mesna). Eur. J. Cancer Clin. Oncol. 1982, 18:1377-1387.
29. Buzadar A.V., Marcus C., Smith T.L., Blumenschein G.R. Early and delayed clinical cardiotoxicity of doxorubicin. Cancer 1985, 55:2761-2765.
30. Campos Y., Huertas R., Lorenzo G., Bautista J., Gutierrez E., Aparicio M., Alesso L., Arenas J. Plasma carnitine insufficiency and effectiveness of L-carnitine therapy in patients with mitochondrial myopathy. Muscle Nerve 1993, 16:150-153.
31. Cacciatore L., Cerio R., Ciarimboli M., Cocozza M., Coto V., D'Alessandro A., D'Alessandro L., Grattarola G., Imparato L., Lingetti M. The therapeutic effect of L-carnitine in patients with exercise-induced stable angina: a controlled study. Drugs Exp. Clin. Res. 1991, 17:225-235.
32. Carter S.K. Adriamycin - a review. J. Natl. Cancer Inst. 1975, 55:1265-1274.
33. Chang B., Nishikawa M., Sato E., Utsumi K., Inoue M. L-carnitine inhibits cisplatin-induced injury of the kidney and small intestine. Arch. Biochem. Biophys. 2002, 405:55-64.
34. Cipolla M.J., Nicoloff A., Rebello T., Amato A., Porter J.M. Propionyl-L-carnitine dilates human subcutaneous arteries through an endothelium-dependent mechanism. J. Vasc. Surg. 1999, 29:1097-1103.
35. Colvin O.M. An overview of cyclophosphamide development and clinical applications. Curr. Pharm. 1999, 5:555-560.
36. Daba M.H., Abdel-Aziz A.A., Moustafa A.M., Al-Majed A.A., Al-Shabanah O.A., El-Kashef H.A. Effects of L-carnitine and ginkgo biloba extract (EG b 761) in experimental bleomycin-induced lung fibrosi. Pharmacol. Res. 2002, 45:461-467.
37. Darweesh, A.Q., 2009. Possible mechanisms of oxazaphosphorines-induced cardiotoxicity in normal and carnitine-depleted rats. M.Sc. Thesis, King Saud University.
38. De Leonardis V., Neri B., Bacalli S., Cinelli P. Reduction of cardiac toxicity of anthracyclines by L-carnitine: preliminary overview of clinical data. Int. J. Clin. Pharmacol. Res. 1985, 5:137-142.
39. De Leonardis V., De Scalzi M., Neri B., Bartalucci S., Cinelli P. Echocardiographic assessment of anthracycline cardiotoxicity during different therapeutic regimens. Int. J. Clin. Pharmacol. Res. 1987, 7:307-311.
40. Debska-Slizien A., Owczarzak A., Król E. The influence of L-carnitine and simultaneous erythropoetin and L-carnitine administration on erythrocyte metabolism in hemodialysis patients. Adv. Ren. Nutr. Metab. Ed. Bios. 1997, 137-144.
41. Dewys W.D., Begg C., Lavin P.T., Band P.R., Bennett J.M., Bertino J.R., Cohen M.H., Douglass H.O., Engstrom P.F., Ezdinli E.Z., Horton J., Johnson G.J., Moertel C.G., Oken M.M., Perlia C., Rosenbaum C., Silverstein M.N., Skeel R.T., Sponzo R.W., Tormey D.C. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am. J. Med. 1980, 69:491-497.
42. Dubourg L., Michoudet C., Cochat P., Baverel G. Human kidney tubules detoxify chloroacetaldehyde, a presumed nephrotoxic metabolite of ifosfamide. J. Am. Soc. Nephrol. 2001, 12:1615-1623.
43. El-Beshlawy A., El Accaoui R., Abd El-Sattar M., Gamal El-Deen M.H., Youssry I., Shaheen N., Hamdy M., El-Ghamrawy M., Taher A. Effect of L-carnitine on the physical fitness of thalassemic patients. Ann. Hematol. 2007, 86:31-34.
44. El-Beshlawy A., Ragab L., Fattah A.A., Ibrahim I.Y., Hamdy M., Makhlouf A., Aoun E., Hoffbrand V., Taher A. Improvement of cardiac function in thalassemia major treated with L-carnitine. Acta Haematol. 2004, 111:143-148.
45. El-Beshlawy A., Seoud H., Ibrahim A., Youssry I., Gabre H., Isma'eel H., Aoun E., Taher A. Apoptosis in thalassemia major reduced by a butyrate derivative. Acta Haematol. 2005, 114:155-159.
46. El-Beshlawy A., Youssry I., El-Saidi S., El Accaoui R., Mansi Y., Makhlouf A., Taher A. Pulmonary hypertension in beta-thalassemia major and the role of L-carnitine therapy. Pediatr. Hematol. Oncol. 2008, 25:734-743.
47. Engel A.G., Rebouche C.J. Carnitine metabolism and inborn errors. J. Inher. Metabol. Dis. 1984, 7:38-43.
48. Fatani A.G., Darweesh A.Q., Rizwan L., Aleisa A.M., Al-Shabanah O.A., Sayed-Ahmed M.M. Carnitine deficiency aggravates cyclophosphamide-induced cardiotoxicity in rats. Chemotherapy 2010, 56:71-81.
49. Friedman S., Fraenkel G. Reversible enzymatic acetylation of carnitine. Arch. Biochem. Biophys. 1955, 51:491-501.
50. Fritz I.B. The effect of muscle extracts on the oxidation of palmitic acid by liver slices and homogenates. Acta Physiol. Scand. 1955, 34:367-385.
51. Goormaghtih E., Ruysschaert J.M. Anthracycline glycoside-membrane interactions. Biochim. Biophys. Acta 1984, 779:271-288.
52. Graziano F., Bisonni R., Catalano V., Silva R., Rovidati S., Mencarini E., Ferraro B., Canestrari F., Baldelli A.M., De Gaetano A., Giordani P., Testa E., Lai V. Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients. Br. J. Cancer 2002, 86:1854-1857.
53. Gulewitsch W., Krimberg R. Zur Kenntunis der extraktionsstoffe der muskeln. 2. Mittei-lung uber das carnitine. Hoppe-Seyler's Z. Physiol. Chem. 1905, 45:326-330.
54. Harper P., Elwin C.E., Cederblad G. Pharmacokinetics of intravenous and oral bolus doses of L-carnitine in healthy subjects. Eur. J. Clin. Pharmacol. 1988, 35:555-562.
55. Haschke M., Vitins T., Lüde S., Todesco L., Novakova K., Herrmann R., Krähenbühl S. Urinary excretion of carnitine as a marker of proximal tubular damage associated with platin-based antineoplastic drugs. Nephrol. Dial. Transplant. 2010, 25:426-433.
56. Heuberger W., Berardi S., Jacky E., Pey P., Krahenbuhl S. Increased urinary excretion of carnitine in patients treated with cisplatin. Eur. J. Clin. Pharmacol. 1998, 54:503-508.
57. Hoang B.X., Graeme Shaw D., Pham P., Levine S. Restoration of cellular energetic balance with L-carnitine in the neuro-bioenergetic approach for cancer prevention and treatment. Med. Hypotheses 2007, 69:262-272.
58. Hockenberry M.J., Hooke M.C., Gregurich M., McCarthy K. Carnitine plasma levels and fatigue in children/adolescents receiving cisplatin, ifosfamide, or doxorubicin. J. Pediatr. Hematol. Oncol. 2009, 31:664-669.
59. Hofmann U., Eichelbaum M., Seefried S., Meese C.O. Identification of thiodiglycolic acid, thiodiglycolic acid sulfoxide, and (3-carboxymethylthio)lactic acid as major human biotransformation products of S-carboxymethyl-L-cysteine. Drug Metab. Dispos. 1991, 19:222-226.
60. T). Bull. Chem. Soc. Jpn 1962, 35:1153-1155.
61. Kantrowitz N.E., Bristow M.R. Cardiotoxicity of antitumor agents. Prog. Cardiovasc. Dis. 1984, 27:195-200.
62. Kashfi K., Israel M., Sweatman T.W., Seshadri R., Cook G.A. Inhibition of mitochondrial carnitine palmitoyltransferases by adriamycin and adriamycin analogues. Biochem. Pharmacol. 1990, 40:1441-1448.
63. Krähenbühl S., Reichen J. Carnitine metabolism in patients with chronic liver disease. Hepatology 2003, 25:148-153.
64. Kuhlmann M.K., Burkhardt G., Kohler H. Insights into potential cellular mechanisms of cisplatin nephrotoxicity and their clinical application. Nephrol. Dial. Transplant. 1997, 12:2478-2480.
65. Kutscher F. Uber liebigs fleischextrakt. Mitteilung I. Z. Unters Nahr. Genubm 1905, 10:528-537.
66. Lefrak E.A., Pitha J., Rosenhiem J., Gotibieb J.H. A clinicopathological analysis of adriamycin cardiotoxicity. Cancer 1973, 32:303-309.
67. Lieberthal W., Triaca V., Levine J. Mechanisms of death induced by cisplatin in proximal tubular epithelial cells: apoptosis vs necrosis. Am. J. Physiol. 1996, 240:F700-F708.
68. Loehrer P.J., Einhom L.H. Cisplatin. Ann. Intern. Med. 1984, 100:704-713.
69. Ludeman S.M. The chemistry of the metabolites of cyclophosphamide. Curr. Pharm. 1999, 5:627-634.
70. Luo X.O., Mo Y., Ke Z.Y., Xu L., Jiang X.Y., Zhang T.T., Chen S.M. High-dose chemotherapy without stem cell transplantation for refractory childhood systemic lupus erythematosus. Chemotherapy 2008, 54:331-335.
71. Maestri A., De Pasquale Ceratti A., Cundari S., Zanna C., Cortesi E., Crinò L. A pilot study on the effect of acetyl-L-carnitine in paclitaxel- and cisplatin-induced peripheral neuropathy. Tumori 2005, 91:135-138.
72. Malaguarnera M., Risino C., Gargante M.P., Oreste G., Barone G., Tomasello A.V., Costanzo M., Cannizzaro M.A. Decrease of serum carnitine levels in patients with or without gastrointestinal cancer cachexia. World J. Gastroenterol. 2006, 12:4541-4545.
73. Mancinelli A., D'Iddio S., Bisonni R., Graziano F., Lippe P., Calvani M. Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment. Cancer Chemother. Pharmacol. 2007, 60:19-26.
74. Mancinelli A., Longo A., Shanahan K., Evans A.M. Disposition of L-carnitine and acetyl-L-carnitine in the isolated perfused rat kidney. J. Pharmacol. Exp. Ther. 1995, 274:1122-1128.
75. Marthaler N.P., Theresa Visarius T., Kupfer A., Lauterburg B.H. Increased urinary losses of carnitine during ifosfamide chemotherapy. Cancer Chemother. Pharmacol. 1999, 44:170-172.
76. Martinez G., Costantino G., Clementi A., Puglia M., Clementi S., Cantarella G., De Meo L., Matera M. Cisplatin-induced kidney injury in the rat: L-carnitine modulates the relationship between MMP-9 and TIMP-3. Exp. Toxicol. Pathol. 2009, 61:183-188.
77. Matalliotakis I., Koumantaki Y., Evageliou A., Matalliotakis G., Goumenou A., Koumantakis E. L-carnitine levels in the seminal plasma of fertile and infertile men: correlation with sperm quality. Int. J. Fertil. Womens Med. 2002, 45:236-240.
78. McFalls E.O., Paulson D.J., Gilbert E.F., Shug A.L. Carnitine protection against adriamycin-induced cardiomyopathy in rats. Life Sci. 1986, 38:497-505.
79. Mir S., Kantar M., Yalaz M., Keskinoglu A., Coker I., Huseyinov A. Effect of hemodialysis on carnitine levels in children with chronic renal failure. Pediatr. Int. 2002, 44:70-73.
80. Mortensen S.A., Aabo K., Jonsson T., Baandrup U. Clinical and non-invasive assessment of anthracycline cardiotoxicity: perspectives on myocardial protection. Int. J. Clin. Pharmacol. Res. 1986, 6:137-150.
81. Murphy S.B., Bowman W.P., Abromowitch M., Mirro J., Ochs J., Rivera G., Pui C.H., Berard F.D. Results of treatment of advanced-stage Burkitt's lymphoma and B cell (SIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine. J. Clin. Oncol. 1986, 4:1732-1739.
82. Myers C.E., Chabner B.A. Anthracyclines. Cancer Chemotherapy: Principles and Practice 1990, 356-381. J.B. Lippincott Co., Philadelphia. B.A. Chabner, J.M. Collins (Eds.).
83. Neri B., Cini-Neri G., Bartalucci S., Bandinelli M. Protective effect of L-carnitine on cardiac metabolic damage induced by doxorubicin in vitro. Anticancer Res. 1986, 6:659-662.
84. Paterna S., Furitano G., Scaffidi L., Barbarino C., Campisi D., Parisi D., Carreca I. Effects of L-carnitine on adriamycin-induced cardiomyopath in rabbit. Int. J. Tissue React. 1984, 6:91-95.
85. Pisano C., Pratesi G., Laccabue D., Zunino F., Lo Giudice P., Bellucci A., Pacifici L., Camerini B., Vesci L., Castorina M., Cicuzza S., Tredici G., Marmiroli P., Nicolini G., Galbiati S., Calvani M., Carminati P., Cavaletti G. Paclitaxel and cisplatin-induced neurotoxicity: a protective role of acetyl-L-carnitine. Clin. Cancer Res. Clin. Cancer Res. 2003, 9(15):5756-5767.
86. Pola P., De Martini D., Gerardino L., De Rossi S., Tondi P. The action of propionyl-L-carnitine on the vasal endothelium: increased t-PA synthesis and a decrease in the activity of PAI-1. A preliminary study. Drugs Exp. Clin. Res. 1992, 18:343-348.
87. Preiss R., Baumann F. Cyclophosphamide and related anticancer drugs. J. Chromatogr. B Biomed. Sci. Appl. 2001, 764:173-192.
88. Rebouche C.J., Chenard C.A. Metabolic fate of dietary carnitine in human adults: identification and quantification of urinary and fecal metabolites. J. Nutr. 1991, 121:539-546.
89. Rebouche C.J., Lehman L.J., Olson L. Epsilon-N-trimethyllysine availability regulates the rate of carnitine biosynthesis in the growing rat. J. Nutr. 1986, 116:751-759.
90. Rebouche C.J. Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism. Ann. NY Acad. Sci. 2004, 1033:30-41.
91. Rizzon P., Biasco G., Di Biase M., Boscia F., Rizzo U., Minafra F., Bortone A., Siliprandi N., Procopio A., Bagiella E., et al. High doses of L-carnitine in acute myocardial infarction: metabolic and antiarrhythmic effects. Eur. Heart J. 1989, 10:502-508.
92. Rossi F., Filippelli W., Russo S., Filippelli A., Berrino L. Cardiotoxicity of doxorubicin: effects of drugs inhibiting the release of vasoactive substances. Pharmacol. Toxicol. 1994, 75:99-107.
93. Sayed-Ahmed M.M., Salman T.M., Gaballah H.E., Abou-El-Naga S.A., Raffaella, Nicolai R., Calvani Propionyl-L-carnitine as protector against adriamycin-induced cardiomyopathy. Pharmacol. Res. 2001, 43:513-520.
94. Sayed-Ahmed M.M., Al-Shabanah O.A., Hafez M.M., Aleisa A.M., Al-Rejaie S.S. Inhibition of gene expression of heart fatty acid binding protein and organic cation/carnitine transporter in doxorubicin cardiomyopathic rat model. Eur. J. Pharmacol. 2010, 640:143-149.
95. Sayed-Ahmed M.M., Mansour H.H., Gharib O.A., Hafez H.F. Acetyl-L-carnitine modulates bleomycin-induced oxidative stress and energy depletion in lung tissues. J. Egypt. Natl. Cancer Inst. 2004, 16(4):237-243.
96. Sayed-Ahmed M.M., Rishk A.M., Soloma S., Abdel-aleem S. Protection by L-carnitine against the inhibition of gene expression of heart fatty acid binding protein by chronic administration of doxorubicin. J. Egypt. Natl. Cancer Inst. 2000, 12:275-281.
97. Sayed-Ahmed M.M., Shaarawy S., Shouman S.A., Osman A.M. Reversal of doxorubicin-induced cardiac metabolic damage by L-carnitine. Pharmacol. Res. 1999, 39:289-295.
98. Sayed-Ahmed M.M., Khattab M., Khalifa A., El-Khabany M. And Osman, A.M: Potenial promise of using L-carnitine and Coenzyme Q10 as protective agents against cisplatin-induced nephrotoxicity. J. Egypt. Natl. Cancer Inst. 1999, 11:167-173.
99. Sayed-Ahmed M.M., Shouman S.A., Rezk B.M., Khalifa M.H., Osman A.M., El-Merzabani M.M. Propionyl-L-carnitine as potential protective agent against adriamycin-induced impairment of fatty acid beta-oxidation in isolated heart mitochondria. Pharmacol. Res. 2000, 41:143-150.
100. Seguro A.C., Shimizu M.H., Kudo L.H., dos Santos Rocha A. Renal concentration defect induced by cisplatin. The role of thick ascending limb and papillary collecting duct. Am. J. Nephrol. 1989, 9:59-65.
101. Shug A.L. Protection from adriamycin-induced cardiomyopathy in rats. Z. Kardiol. 1987, 76:46-52.
102. Siliprandi N., Menabo Di Lisa R., Ciman M., Sartorelli L. Transport and function of carnitine in muscle. J. Clin. Chem. Clin. Biochem. 1990, 28:303-306.
103. Spagnoli L.G., Corsi M., Villaschi S., Palmieri G., Maccari F. Myocardial carnitine deficiency in acute myocardial infarction. Lancet 1982, 1:1419-1420.
104. Steiber A., Kerner J., Hoppel C.L. Carnitine: a nutritional, biosynthetic, and functional perspective. Mol. Aspects Med. 2004, 25:455-473.
105. Steinmann B., Bachmann C., Colombo J.P., Gitzelmann R. The renal handling of carnitine in patients with selective tubulopathy and with Fanconi Syndrome. Pediatr. Res. 1987, 21:201-204.
106. Stewart D.J., Morgan L.R., Verma S., Maroun J.A., Thibault M. Pharmacology, relative bioavailability, and toxicity of three different oral cyclophosphamide preparations in a randomized, cross-over study. Invest. New Drugs 1995, 13:99-107.
107. Stieger B., O'Neill B., Krahenbuhl S. Characterization of L-carnitine transport by rat kidney brush-border membrane vesicles. Biochem. J. 1995, 309:393-402.
108. Strauss M., Anselmi G., Hermoso T., Tejero F. Carnitine promotes heat shock protein synthesis in adriamycin-induced cardiomyopathy in a neonatal rat experimental model. J. Mol. Cell. Cardiol. 1998, 30:2319-2325.
109. Tamai I., Ohashi R., Nezu J., Yabuuchi H., Oku A., Shimane M., Sai Y., Tsuji A. Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2. J. Biol. Chem. 1998, 273:20378-20382.
110. Tanphaichitr V., Leelahagul P. Carnitine metabolism and human carnitine deficiency. Nutrition 1993, 9:246-254.
111. Tein I., Bukovac S.W., Xie Z.W. Characterization of the human plasmalemmal carnitine transporter in cultured skin fibroblasts. Arch. Biochem. Biophys. 1996, 329:145-155.
112. Tomita M., Senju Y. Uber die aminoverbindungen, welche die Biuretreaktion zeigen. III. Spaltungen der γ-Amino-β-oxybuttersaure in die optisch aktiven komponenten. Hoppe-Seyler's Z. Physiol. Chem. 1927, 169:263-277.
113. Toomey D., Redmond H.P., Bouchier-Hayes D. Mechanisms mediating cancer cachexia. Cancer 1995, 76:2418-2426.
114. Tufekci O., Gunes D., Ozoĝul C., Kolatan E., Altun Z., Yilmaz O., Aktaş S., Erbayraktar Z., Kirkim G., Mutafoĝlu K., Soylu A., Serbetçioĝlu B., Güneri E.A., Olgun N. Evaluation of the effect of acetyl L-carnitine on experimental cisplatin nephrotoxicity. Chemotherapy 2009, 55:451-459.
115. Van Vleet J., Ferrans V., Weririch W. Cardiac disease induced by chronic adriamycin administration in dogs and an evaluation of vitamin E and selenium as cardioprotectants. Am. J. Pathol. 1980, 99:13-42.
116. Venkatesan N. Curcumin attenuation of acute adriamycin myocardial toxicity in rats. Br. J. Pharmacol. 1998, 124:425-427.
117. Vinci E., Rampello E., Zanoli L., Oreste G., Pistone G., Malaguarnera M. Serum carnitine levels in patients with tumoral cachexia. Eur. J. Intern. Med. 2005, 16:419-423.
118. Visarius T.M., Stucki J.W., Lauterburg B.H. Inhibition and stimulation of long-chain fatty acid oxidation by chloroacetaldehyde and methylene blue in rats. J. Pharmacol. Exp. Ther. 1999, 289:820-824.
119. Waldner R., Laschan C., Lohninger A., Gessner M., Tüchler H., Huemer M., Spiegel W., Karlic H. Effects of doxorubicin-containing chemotherapy and a combination with L-carnitine on oxidative metabolism in patients with non Hodgkin lymphoma. J. Cancer Res. Clin. Oncol. 2006, 132:121-128.
120. Yaris N., Ceviz N., Coskun T., Akytuz C., Buyukpamukcu M. Serum carnitine levels during the doxorubicin therapy. Its role in cardiotoxicity. J. Exp. Clin. Cancer Res. 2002, 21:165-170.
121. Yeung T.K., Jaenke R.S., Wilding D., Creighton A.M., Hopewell J.W. The protective activity of ICRF-187 against doxorubicin-induced cardiotoxicity in the rat. Cancer Chemother. Pharmacol. 1992, 30:58-64.
122. Yoon H.R., Hong Y.M., Boriack R.L., Bennett M.J. Effect of L-carnitine supplementation on cardiac carnitine palmitoyltransferase activities and plasma carnitine concentrations in adriamycin-treated rats. Pediatr. Res. 2003, 53:788-792.
123. Zdrojkowska-Krol E., Karpowicz B., Rutkowski B. Reference values of carnitine in plasma and urine. Diag. Lab. 1994, 30:413-420.
124. Zeidan Q., Strauss M., Porras N., Anselmi G. Differential long-term subcellular responses in heart and liver to adriamycin stress. Exogenous L-carnitine cardiac and hepatic protection. J. Submicrosc. Cytol. Pathol. 2002, 34:315-321.
125. Zhang J.G., Lindup W.E. Role of mitochondria in cisplatin-induced oxidative damage exhibited by rat renal cortical slices. Biochem. Pharmacol. 1993, 45:2215-2222.